Dydroge steron, Estradiol | Femoston 1 tablet is covered.pl.ob. 28 pcs.
Special Price
$34.92
Regular Price
$43.00
In stock
SKU
BID461778
Latin name
Femoston
Femoston
Latin name
Femoston
release form
film-coated tablets
Packing
28 pcs.
Indications
Hormone replacement therapy for symptoms of estrogen deficiency treatment of menopausal menopause associated with natural or surgical menopause.
Prevention of postmenopausal osteoporosis in women with a high risk of fractures with intolerance or contraindications to other drugs for the prevention of osteoporosis
Contraindications
established or suspected pregnancy
period of lactation (breastfeeding)
diagnosed or suspected breast cancer with a history of
diagnosed or suspected estrogen-dependent malignant neoplastic diseases or blood vessels pulmonary thromboembolism)
active or recent arterial t rhomboembolism
acute liver disease, as well as a history of liver disease (before normalization of laboratory parameters of liver function)
untreated endometrial hyperplasia
porphyria
hypersensitivity to the drug.
Use with caution and under the supervision of a physician in patients receiving HRT and having the following conditions (currently or in history): uterine leiomyoma, endometriosis, thrombosis, and a history of their risk factors in the presence of risk factors for estrogen-dependent tumors (e.g. cancer of the patient’s mother), arterial hypertension, benign liver tumor, diabetes mellitus, cholelithiasis, epilepsy, migraine or intense headache, history of endometrial hyperplasia, systemic lupus erythematosus, bronchial asthma, renal failure, otosclerosis.
Use during pregnancy and lactation
The drug is contraindicated in pregnancy and lactation (breastfeeding).
If pregnancy occurs during treatment with Femoston, therapy should be stopped immediately.
Composition
1 tablet contains:
Active ingredients:
estradiol 1 mg,
dydrogesterone 10 mg
Excipients:
lactose monohydrate,
magnesium sulfide, srdlp
Dosage and administration of
Femoston 1/10 take 1 tablet per day (preferably at the same time of day) without a break.
In the first 14 days of the 28-day cycle, take 1 tablet of white color daily (from half of the package with an arrow marked with the number 1) containing 1 mg of estradiol, and for the remaining 14 days, take 1 tablet of gray color (from half of the package with arrow marked 2) containing 1 mg of estradiol and 10 mg of dydrogesterone.
Side effects
From the reproductive system: breast tenderness is possible, breakthrough bleeding, pelvic pain sometimes - changes in cervical erosion, changes in secretion, dysmenorrhea rarely - enlargement of the mammary glands, premenstrual-like syndrome in some cases - a change in libido.
From the digestive system: nausea, flatulence, abdominal pain are possible sometimes - cholecystitis is rare (0.01-0.1%) - impaired liver function, in some cases accompanied by asthenia, malaise, jaundice or abdominal pain is very rare - vomiting.
From the side of the central nervous system: headache, migraine (1-10%) sometimes (0.1-1%) - dizziness, nervousness, depression are very rare - chorea.
From the cardiovascular system: sometimes - venous thromboembolism is very rare - myocardial infarction.
From the hemopoietic system: very rarely (less than 0.01%) - hemolytic anemia.
Dermatological reactions: sometimes - rash, itching very rarely - chloasma, melasma, erythema polymorphic, erythema nodosum, hemorrhagic purpura.
Allergic reactions: sometimes - urticaria in some cases - angioedema.
Other: changes in body weight sometimes — vaginal candidiasis, breast carcinoma, rarely an increase in leiomyoma — peripheral edema, intolerance to contact lenses, increased corneal curvature in some cases (less than 0.01%) —exacerbation of porphyria.
Drug Interaction
Concurrent administration of drugs that are inducers of microsomal liver enzymes (including barbiturates, phenytoin, rifampicin, rifabutin, carbamazepine) may attenuate the estrogenic effect of the drug.
Ritonavir and nelfinavir, although known as microsomal metabolism inhibitors, may play the role of inducers when co-administered with steroid hormones.
Herbal preparations containing St. John's wort can stimulate the exchange of estrogens and progestogens.
The interaction of dydrogesterone, part of the drug Themoston, with other medicines is not known.
Overdose
Symptoms: nausea, vomiting, drowsiness, dizziness.
Treatment: symptomatic therapy.
Storage conditions
The drug should be stored out of the reach of children, at a temperature not exceeding 30 РC.
Shelf suitability
3 Year
Active ingredient
Dydrogesterone, Estradiol
dosage form srdl kp Dosage form
tablets
Femoston
release form
film-coated tablets
Packing
28 pcs.
Indications
Hormone replacement therapy for symptoms of estrogen deficiency treatment of menopausal menopause associated with natural or surgical menopause.
Prevention of postmenopausal osteoporosis in women with a high risk of fractures with intolerance or contraindications to other drugs for the prevention of osteoporosis
Contraindications
established or suspected pregnancy
period of lactation (breastfeeding)
diagnosed or suspected breast cancer with a history of
diagnosed or suspected estrogen-dependent malignant neoplastic diseases or blood vessels pulmonary thromboembolism)
active or recent arterial t rhomboembolism
acute liver disease, as well as a history of liver disease (before normalization of laboratory parameters of liver function)
untreated endometrial hyperplasia
porphyria
hypersensitivity to the drug.
Use with caution and under the supervision of a physician in patients receiving HRT and having the following conditions (currently or in history): uterine leiomyoma, endometriosis, thrombosis, and a history of their risk factors in the presence of risk factors for estrogen-dependent tumors (e.g. cancer of the patient’s mother), arterial hypertension, benign liver tumor, diabetes mellitus, cholelithiasis, epilepsy, migraine or intense headache, history of endometrial hyperplasia, systemic lupus erythematosus, bronchial asthma, renal failure, otosclerosis.
Use during pregnancy and lactation
The drug is contraindicated in pregnancy and lactation (breastfeeding).
If pregnancy occurs during treatment with Femoston, therapy should be stopped immediately.
Composition
1 tablet contains:
Active ingredients:
estradiol 1 mg,
dydrogesterone 10 mg
Excipients:
lactose monohydrate,
magnesium sulfide, srdlp
Dosage and administration of
Femoston 1/10 take 1 tablet per day (preferably at the same time of day) without a break.
In the first 14 days of the 28-day cycle, take 1 tablet of white color daily (from half of the package with an arrow marked with the number 1) containing 1 mg of estradiol, and for the remaining 14 days, take 1 tablet of gray color (from half of the package with arrow marked 2) containing 1 mg of estradiol and 10 mg of dydrogesterone.
Side effects
From the reproductive system: breast tenderness is possible, breakthrough bleeding, pelvic pain sometimes - changes in cervical erosion, changes in secretion, dysmenorrhea rarely - enlargement of the mammary glands, premenstrual-like syndrome in some cases - a change in libido.
From the digestive system: nausea, flatulence, abdominal pain are possible sometimes - cholecystitis is rare (0.01-0.1%) - impaired liver function, in some cases accompanied by asthenia, malaise, jaundice or abdominal pain is very rare - vomiting.
From the side of the central nervous system: headache, migraine (1-10%) sometimes (0.1-1%) - dizziness, nervousness, depression are very rare - chorea.
From the cardiovascular system: sometimes - venous thromboembolism is very rare - myocardial infarction.
From the hemopoietic system: very rarely (less than 0.01%) - hemolytic anemia.
Dermatological reactions: sometimes - rash, itching very rarely - chloasma, melasma, erythema polymorphic, erythema nodosum, hemorrhagic purpura.
Allergic reactions: sometimes - urticaria in some cases - angioedema.
Other: changes in body weight sometimes — vaginal candidiasis, breast carcinoma, rarely an increase in leiomyoma — peripheral edema, intolerance to contact lenses, increased corneal curvature in some cases (less than 0.01%) —exacerbation of porphyria.
Drug Interaction
Concurrent administration of drugs that are inducers of microsomal liver enzymes (including barbiturates, phenytoin, rifampicin, rifabutin, carbamazepine) may attenuate the estrogenic effect of the drug.
Ritonavir and nelfinavir, although known as microsomal metabolism inhibitors, may play the role of inducers when co-administered with steroid hormones.
Herbal preparations containing St. John's wort can stimulate the exchange of estrogens and progestogens.
The interaction of dydrogesterone, part of the drug Themoston, with other medicines is not known.
Overdose
Symptoms: nausea, vomiting, drowsiness, dizziness.
Treatment: symptomatic therapy.
Storage conditions
The drug should be stored out of the reach of children, at a temperature not exceeding 30 РC.
Shelf suitability
3 Year
Active ingredient
Dydrogesterone, Estradiol
dosage form srdl kp Dosage form
tablets
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review